Chi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO Virtual Congress 2020

HONG KONG and FLORHAM PARK, N.J., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the studies of surufatinib and fruquintinib will be presented at the upcoming European Society for Medical Oncology (ESMO) Virtual Congress 2020, taking place on September 17-21, 2020.

Further details of the presentations are as follows:

SURUFATINIB

Title:	Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumors (SANET-p): a randomized, double-blind, placebo (P)-controlled Phase III trial (NCT02589821)
Lead Author:	Jianming Xu, Head of the Department of Gastrointestinal Oncology, The Fifth Medical Center, General Hospital of the PLA
Session:	Proffered Paper - NETs
Abstract #:	1156O
Date & Time:	Sunday, September 20, 2020 2:25 PM CEST
Room:	Channel 3
Title:	Subgroup analysis by Ki-67 and primary tumor origins of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated extrapancreatic neuroendocrine tumors (SANET-ep)
Lead Author:	Zhiwei Zhou, Director, Department of Gastric and Pancreatic Surgery, Sun Yat-sen University Cancer Center
Session:	e-Poster Display Session
Abstract #:	1165P
Date available:	Thursday, September 17, 2020

FRUQUINTINIB

Title:	Phase (Ph) 1/1b Trial of Fruquintinib (Fru) in Patients (Pts) with Advanced Solid Tumors: Preliminary Results of the Dose Expansion (Exp) Cohort in Refractory Metastatic Colorectal Cancer (mCRC)
Lead Author:	N. Arvind Dasari, Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Session:	e-Poster Display Session
Abstract #:	458P
Date available:	Thursday, September 17, 2020

About Surufatinib